Drug Puts A $750,000 ‘Price Tag On Life’

KHN Original

The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.

Obamacare Exchanges In Limbo

KHN Original

The failure this week of the U.S. Senate’s ACA repeal effort was one more twist in the ongoing political drama that has complicated routine rate setting for insurers and state officials.